InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.175

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$105 Paradigms preclinical hay fever trial published 16 May 2017 8:29AM $0.585 $0.175 fallen by 70.09%
$105 Paradigm Non-Deal Roadshow Presentation 15 May 2017 4:36PM $0.585 $0.175 fallen by 70.09%
$105 Paradigm Government grant for Ross River virus research 11 May 2017 9:28AM n/a $0.175 n/a
$105 Paradigm March Quarter Update & Appendix 4C 28 Apr 2017 9:37AM $0.510 $0.175 fallen by 65.69%
$105 Final participant treated in Phase 2 hay fever trial 23 Mar 2017 9:12AM $0.450 $0.175 fallen by 61.11%
$105 Paradigm receives $1.34 million R&D tax incentive rebate 22 Mar 2017 9:25AM $0.450 $0.175 fallen by 61.11%
$105 Paradigm Presents to Asian Investors 21 Mar 2017 9:15AM $0.450 $0.175 fallen by 61.11%
$105 Paradigm Update Ross River Virus Clinical Trial 7 Mar 2017 1:47PM $0.395 $0.175 fallen by 55.70%
$105 Broker Research Report for Paradigm Biopharma 2 Mar 2017 9:37AM $0.405 $0.175 fallen by 56.79%
$105 Half Year Accounts 24 Feb 2017 5:10PM $0.410 $0.175 fallen by 57.32%
$105 Appendix 3B 7 Feb 2017 4:07PM $0.400 $0.175 fallen by 56.25%
$105 Quarterly Cashflow Report 31 Jan 2017 2:56PM $0.470 $0.175 fallen by 62.77%
$105 Recruitment complete in Paradigms hay fever clinical trial 25 Jan 2017 9:14AM $0.455 $0.175 fallen by 61.54%
$105 Shares released from escrow 20 Jan 2017 10:42AM $0.430 $0.175 fallen by 59.30%
$105 Appendix 3B 19 Jan 2017 10:01AM $0.450 $0.175 fallen by 61.11%
$105 Broker Initiated Coverage 16 Dec 2016 12:29AM $0.400 $0.175 fallen by 56.25%
$105 Change of Director's Interest Notice 15 Dec 2016 11:29AM $0.400 $0.175 fallen by 56.25%
$105 Change of Director's Interest Notice 9 Dec 2016 5:40PM $0.420 $0.175 fallen by 58.33%
$105 Change of Director's Interest Notice 9 Dec 2016 5:38PM $0.420 $0.175 fallen by 58.33%
$105 Change in substantial holding 9 Dec 2016 9:24AM $0.440 $0.175 fallen by 60.23%
$105 Change of Director's Interest Notice 9 Dec 2016 9:19AM $0.440 $0.175 fallen by 60.23%
$105 Appendix 3B 9 Dec 2016 9:17AM $0.440 $0.175 fallen by 60.23%
$105 Closure of SPP 2 Dec 2016 4:35PM $0.400 $0.175 fallen by 56.25%
$105 Managing Director's Presentation to AGM 30 Nov 2016 9:28AM $0.430 $0.175 fallen by 59.30%
$105 Results of Annual General Meeting 30 Nov 2016 12:40AM $0.435 $0.175 fallen by 59.77%

626 - 650 of 720 results

Page 26 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.